Avgerinos I, et al. - In adult patients with type 2 diabetes, researchers evaluated the impact of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on microvascular endpoints via conducted a systematic review and meta-analysis of randomized controlled trials. Sixty studies with 60,077 patients were included in this analysis. The findings demonstrated that GLP-1 RAs were safe regarding nephropathy- and retinopathy-related outcomes. Compared with placebo, the incidence of vitreous haemorrhage was higher in patients treated with GLP-1 RAs. Therefore, attention might be warranted for the incidence of vitreous haemorrhage.